Tip sheet from TRACIE updated February 10, 2021.

Before ordering laboratory testing for post-COVID conditions, the goals of testing should be clear to the healthcare professional and to the patient. Laboratory testing should be guided by the patient history, physical examination, and clinical findings.

The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization. Eligibility for patients considered high risk.

It is important for healthcare professionals to listen to and validate patients’ experiences, recognizing that diagnostic testing results may be within normal ranges even for patients whose symptoms and conditions negatively impact their quality of life, functioning (i.e., with activities of daily living), and ability to return to school or work.

Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance – Key Points

It is anticipated that antiviral therapies would have the greatest effect early in the course of the disease, while immunosuppressive/anti-inflammatory therapies are likely to be more beneficial in the later states of COVID-19. No therapy has been proven to be beneficial in outpatients with mild to moderate COVID-19 who are not at high risk for disease progression. The COVID-19 Treatment Guidelines Panel (the Panel) recommends providing supportive care and symptomatic management to outpatients with COVID-19; steps should also be taken to reduce the risk of SARS-CoV-2 transmission to others. Patients should be advised about when to seek in-person evaluation.

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through v-safe, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you and get more information. And v-safe will remind you to get your second COVID-19 vaccine dose if you need one.

This quick reference highlights key COVID-19 Clinical Care information for healthcare providers and provides selected links to full guidance and research for easier CDC web navigation.

Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary cost sharing for these products when used as authorized or approved by the Food and Drug Administration (FDA).

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product high titer COVID-19 convalescent plasma to treat hospitalized patients with COVID-19. Available evidence suggests potential benefit is associated with transfusion of high titer COVID-19 convalescent plasma early in the course of the disease and those hospitalized with impaired humoral immunity. Transfusion of COVID-19 convalescent plasma to hospitalized patients late in the course of illness (e.g., following respiratory failure requiring intubation and mechanical ventilation) has not been associated with clinical benefit.